Foundation for Sarcoidosis Research (FSR) receives confirmation from the Department of Labor (DOL) ensuring patient access to FMLA for participation in clinical trials 
Parexel’s Teri Karcher Named to 2024 PharmaVoice 100
Chief Drug Development Officer and Executive Vice President, Head of Launch Excellence recognized for pioneering leadership in drug development DURHAM,...
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
SARASOTA, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments...
Tonix Pharmaceuticals Announces AI Collaboration with X-Chem to Develop Broad-Spectrum Antivirals
AI (Artificial Intelligence) and ML (Machine Learning) drug discovery collaboration will accelerate the development of small molecules as orally available...
Autonomix Medical, Inc. to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC
Live webcast fireside chat on Tuesday, October 15th at 2:30 PM ET THE WOODLANDS, TX, Oct. 08, 2024 (GLOBE NEWSWIRE)...
SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities
DENVER , Oct. 08, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing...
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to...
Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome
REDWOOD CITY, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing...
Cerevance Achieves Second Milestone in Research Collaboration with Merck
BOSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment...
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
VANCOUVER, Washington, Oct. 08, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing...
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
ATLANTA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet...
STRATA Skin Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
HORSHAM, Pa., Oct. 08, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical...
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
SANTA ANA, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage...
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
CORAL GABLES, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (Nasdaq: CPRX), a commercial-stage...
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
GANZIMMUN Diagnostics to Feature ColoAlert at the 57th Medizinische Woche Baden-BadenBERKELEY, Calif. and MAINZ, Germany, Oct. 08, 2024 (GLOBE NEWSWIRE)...
One Millionth Procedure Completed Using LENSAR’s Cataract Laser Systems
ORLANDO, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology...
ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301
Safety, pharmacokinetics and target engagement data from first-in-human Phase 1 clinical trial in healthy volunteers will potentially enable rapid advancement...
Humacyte Late-Breaking Abstract Accepted for Oral Presentation on V007 Phase 3 AV Access Clinical Trial at the American Society of Nephrology’s Kidney Week 2024
DURHAM, N.C., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable,...
Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
Oak Ridge, TN, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit
CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage...
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
SAN DIEGO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage...